Dr. Feras Almarshad
@ffferas
استاذ الطب الباطني المشارك بكلية الطب بجامعة شقراء و استشاري الطب الباطني وامراض التخثر زمالة التخصص الدقيق بامراض التخثر من جامعة اوتاوا بكندا
ID: 885346488
16-10-2012 21:27:58
931 Tweet
255 Takipçi
444 Takip Edilen
💉 New in AmericanJournalofHematology - The WAVe Study 🩸 In patients >90 kg with cancer-associated VTE, weight-adjusted dalteparin (up to 33,000 IU/day) showed acceptable 30-Day bleeding (5.3%) and low recurrence (1.2%), supporting individualized dosing. 📖 Read: doi.org/10.1002/ajh.70…
🩸 API-CAT Post-hoc of Mahé Isabelle at #ASH25 Predictors of clinically relevant bleeding during extended apixaban for cancer-associated VTE: 📉 Anemia/Thrombocytopenia ↑ risk (HR 1.93) 👴 Age ≥75 ↑ (1.51) 🫁 Index PE ↑ (1.47) ♂️ Male sex ↑ (1.38) Findings consistent
🔍 #ASH25 Highlight presented by Francis Couturaud Extended-treatment data from RENOVE 📘 (post-hoc): Apixaban vs rivaroxaban after ≥6 months of anticoagulation for VTE. 🩸 Bleeding (5-yr CRB): • Full dose: 16.5% API vs 14.4% RIVA (aHR 1.02) • Reduced dose: 11.0% API vs 9.0% RIVA